Comparison of the relative activities of α-tocopherol and PMC on platelet aggregation and antioxidative activity

J. R. Sheu, C. R. Lee, G. Hsiao, W. C. Hung, Y. M. Lee, Y. C. Chen, M. H. Yen

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

In this study, PMC (2,2,5,7,8,-pentamethyl-6-hydroxychromane), a potent antioxidant derived from α-tocopherol, dose-dependently inhibited agonist- induced platelet aggregation in human platelet-rich plasma. PMC is over 5-10 times more potent than α-tocopherol in inhibiting human platelet aggregation. Moreover, PMC (25-350 μM) dose-dependently reduced the relative fluorescence intensity of platelet membrane tagged with diphenylhexatriene (DPH). PMC is about 6-times more potent than α-tocopherol on this effect. Furthermore, antioxidative activity of PMC was investigated using two in vitro models. PMC inhibited non-enzymatic iron-induced lipid peroxidation in rat brain homogenates with an IC50 value of 0.21±0.05 μM. It was more potent than α-tocopherol or other classical antioxidants. PMC also scavenged the stable flee radical 1,1-diphenyl-2-picrylhydrazyl (DPPH). The concentration of PMC resulting in a decrease of 0.20 in the absorbance of DPPH was about 12.1±3.6 μM, was comparable in potency to α-tocopherol, butylated hydroxytoluence and Trolox. The antiplatelet activity of PMC may possibly be due initially to an increase in fluidity of the platelet membrane followed by inhibition of platelet aggregation. Our results indicate that PMC is a potentially effective antioxidant and antiaggregating agent, and could be helpful the design of compounds with more clinical effectiveness.

Original languageEnglish
Pages (from-to)197-206
Number of pages10
JournalLife Sciences
Volume65
Issue number2
Publication statusPublished - Jun 4 1999
Externally publishedYes

Fingerprint

Tocopherols
Platelets
Platelet Aggregation
Agglomeration
Antioxidants
Blood Platelets
Diphenylhexatriene
Membrane Fluidity
Platelet-Rich Plasma
Membranes
Fluidity
Lipid Peroxidation
Inhibitory Concentration 50
Iron
Fluorescence
Rats
Brain
Lipids
Plasmas

Keywords

  • α-tocopherol
  • Antioxidation
  • Platelet aggregation
  • PMC

ASJC Scopus subject areas

  • Pharmacology

Cite this

Comparison of the relative activities of α-tocopherol and PMC on platelet aggregation and antioxidative activity. / Sheu, J. R.; Lee, C. R.; Hsiao, G.; Hung, W. C.; Lee, Y. M.; Chen, Y. C.; Yen, M. H.

In: Life Sciences, Vol. 65, No. 2, 04.06.1999, p. 197-206.

Research output: Contribution to journalArticle

Sheu, J. R. ; Lee, C. R. ; Hsiao, G. ; Hung, W. C. ; Lee, Y. M. ; Chen, Y. C. ; Yen, M. H. / Comparison of the relative activities of α-tocopherol and PMC on platelet aggregation and antioxidative activity. In: Life Sciences. 1999 ; Vol. 65, No. 2. pp. 197-206.
@article{232a9335d8f24ff7b9001f77cc1b05e4,
title = "Comparison of the relative activities of α-tocopherol and PMC on platelet aggregation and antioxidative activity",
abstract = "In this study, PMC (2,2,5,7,8,-pentamethyl-6-hydroxychromane), a potent antioxidant derived from α-tocopherol, dose-dependently inhibited agonist- induced platelet aggregation in human platelet-rich plasma. PMC is over 5-10 times more potent than α-tocopherol in inhibiting human platelet aggregation. Moreover, PMC (25-350 μM) dose-dependently reduced the relative fluorescence intensity of platelet membrane tagged with diphenylhexatriene (DPH). PMC is about 6-times more potent than α-tocopherol on this effect. Furthermore, antioxidative activity of PMC was investigated using two in vitro models. PMC inhibited non-enzymatic iron-induced lipid peroxidation in rat brain homogenates with an IC50 value of 0.21±0.05 μM. It was more potent than α-tocopherol or other classical antioxidants. PMC also scavenged the stable flee radical 1,1-diphenyl-2-picrylhydrazyl (DPPH). The concentration of PMC resulting in a decrease of 0.20 in the absorbance of DPPH was about 12.1±3.6 μM, was comparable in potency to α-tocopherol, butylated hydroxytoluence and Trolox. The antiplatelet activity of PMC may possibly be due initially to an increase in fluidity of the platelet membrane followed by inhibition of platelet aggregation. Our results indicate that PMC is a potentially effective antioxidant and antiaggregating agent, and could be helpful the design of compounds with more clinical effectiveness.",
keywords = "α-tocopherol, Antioxidation, Platelet aggregation, PMC",
author = "Sheu, {J. R.} and Lee, {C. R.} and G. Hsiao and Hung, {W. C.} and Lee, {Y. M.} and Chen, {Y. C.} and Yen, {M. H.}",
year = "1999",
month = "6",
day = "4",
language = "English",
volume = "65",
pages = "197--206",
journal = "Life Sciences",
issn = "0024-3205",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Comparison of the relative activities of α-tocopherol and PMC on platelet aggregation and antioxidative activity

AU - Sheu, J. R.

AU - Lee, C. R.

AU - Hsiao, G.

AU - Hung, W. C.

AU - Lee, Y. M.

AU - Chen, Y. C.

AU - Yen, M. H.

PY - 1999/6/4

Y1 - 1999/6/4

N2 - In this study, PMC (2,2,5,7,8,-pentamethyl-6-hydroxychromane), a potent antioxidant derived from α-tocopherol, dose-dependently inhibited agonist- induced platelet aggregation in human platelet-rich plasma. PMC is over 5-10 times more potent than α-tocopherol in inhibiting human platelet aggregation. Moreover, PMC (25-350 μM) dose-dependently reduced the relative fluorescence intensity of platelet membrane tagged with diphenylhexatriene (DPH). PMC is about 6-times more potent than α-tocopherol on this effect. Furthermore, antioxidative activity of PMC was investigated using two in vitro models. PMC inhibited non-enzymatic iron-induced lipid peroxidation in rat brain homogenates with an IC50 value of 0.21±0.05 μM. It was more potent than α-tocopherol or other classical antioxidants. PMC also scavenged the stable flee radical 1,1-diphenyl-2-picrylhydrazyl (DPPH). The concentration of PMC resulting in a decrease of 0.20 in the absorbance of DPPH was about 12.1±3.6 μM, was comparable in potency to α-tocopherol, butylated hydroxytoluence and Trolox. The antiplatelet activity of PMC may possibly be due initially to an increase in fluidity of the platelet membrane followed by inhibition of platelet aggregation. Our results indicate that PMC is a potentially effective antioxidant and antiaggregating agent, and could be helpful the design of compounds with more clinical effectiveness.

AB - In this study, PMC (2,2,5,7,8,-pentamethyl-6-hydroxychromane), a potent antioxidant derived from α-tocopherol, dose-dependently inhibited agonist- induced platelet aggregation in human platelet-rich plasma. PMC is over 5-10 times more potent than α-tocopherol in inhibiting human platelet aggregation. Moreover, PMC (25-350 μM) dose-dependently reduced the relative fluorescence intensity of platelet membrane tagged with diphenylhexatriene (DPH). PMC is about 6-times more potent than α-tocopherol on this effect. Furthermore, antioxidative activity of PMC was investigated using two in vitro models. PMC inhibited non-enzymatic iron-induced lipid peroxidation in rat brain homogenates with an IC50 value of 0.21±0.05 μM. It was more potent than α-tocopherol or other classical antioxidants. PMC also scavenged the stable flee radical 1,1-diphenyl-2-picrylhydrazyl (DPPH). The concentration of PMC resulting in a decrease of 0.20 in the absorbance of DPPH was about 12.1±3.6 μM, was comparable in potency to α-tocopherol, butylated hydroxytoluence and Trolox. The antiplatelet activity of PMC may possibly be due initially to an increase in fluidity of the platelet membrane followed by inhibition of platelet aggregation. Our results indicate that PMC is a potentially effective antioxidant and antiaggregating agent, and could be helpful the design of compounds with more clinical effectiveness.

KW - α-tocopherol

KW - Antioxidation

KW - Platelet aggregation

KW - PMC

UR - http://www.scopus.com/inward/record.url?scp=0033522969&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033522969&partnerID=8YFLogxK

M3 - Article

C2 - 10416825

AN - SCOPUS:0033522969

VL - 65

SP - 197

EP - 206

JO - Life Sciences

JF - Life Sciences

SN - 0024-3205

IS - 2

ER -